LOGIN  |  REGISTER
Terns Pharmaceuticals

Stryker announces intention to nominate a new director, Rachel Ruggeri

December 07, 2023 | Last Trade: US$364.60 7.46 2.09

Kalamazoo, Michigan, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that its Board of Directors intends to nominate Rachel Ruggeri for election to the Company’s Board of Directors at Stryker’s 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.

Ms. Rachel Ruggeri has over 25 years of global finance leadership experience and serves as the executive vice president and chief financial officer at Starbucks, where she is responsible for the global finance function for the Company, including developing and executing financial strategies. Prior to becoming Starbucks’ chief financial officer, Ms. Ruggeri served as the senior vice president of Global Retail, with responsibility for the retail portfolio including company-operated and licensed/franchised stores across the globe. Ms. Ruggeri also held a variety of finance leadership positions within Starbucks’ North America and US businesses and led its Corporate Finance and Planning function.

Ms. Ruggeri began her career in 1992 as a college instructor and then held finance roles of increasing responsibilities for companies in a variety of sectors prior to joining Starbucks in 2001. She holds a BA from the University of Puget Sound and an MBA from Washington State University.

“We are very pleased about the potential to add Rachel to our Board,” said Kevin Lobo, Chair and Chief Executive Officer. “Rachel will bring strong leadership experience and valuable insights from a highly respected global consumer company.”

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB